Effects of soy isoflavone supplements on bone turnover markers in menopausal women: Systematic review and meta-analysis of randomized controlled trials

Taku, Keisei; Melby, Melissa K.; Kurzer, Mindy S.; Mizuno, Shoichi; Watanabe, Shaw; Ishimi, Yoshiko

doi:10.1016/j.bone.2010.05.001

Cited by 149 publications

(136 citation statements)

References 69 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…(17) Very few randomized controlled trials on soy isoflavones effects on bone have contained data for bCTX and P1NP, and those reported have generally not detected significant effects of soy isoflavone supplements on these bone turnover markers. (18) The heterogeneity of trial results are likely to be a combination of underpowered clinical trials and differences in habitual dietary intake of soy isoflavones, (19) the variable interval since the onset of menopause, (20) as well as the chemical forms and proportions of individual soy isoflavones. (21) The current study sought to minimize these variables by investigating a homogeneous large study population of women who were likely to be at maximal bone turnover by being within the first 2 years of their menopause.…”

Section: Discussionmentioning

confidence: 99%

Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial

Sathyapalan

Aye

Rigby

et al. 2016

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Menopausal estrogen loss leads to an increased bone loss. Soy isoflavones can act as selective estrogen receptor modulators, their role in bone turnover is unclear. The primary outcome was assessing changes in plasma bone turnover markers. The secondary outcomes were assessing changes in cardiovascular risk markers including insulin resistance, blood pressure, and lipid profile. We performed a double-blind randomized parallel study in which 200 women within 2 years after the onset of their menopause were randomized to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (SP), daily for 6 months. There was a significant reduction in type I collagen crosslinked beta C-telopeptide (bCTX) (bone-resorption marker) with SPI supplementation (0.40 AE 0.17 versus 0.15 AE 0.09 mg/L; p < 0.01) compared to SP supplementation (0.35 AE 0.12 versus 0.35 AE 0.13 mg/L; p ¼ 0.92) after 6 months. There was also a significant reduction in type I procollagen-N-propeptide (P1NP) (bone formation marker) with SPI supplementation (50.5 AE 25.0 versus 34.3 AE 17.6 mg/L; p < 0.01), more marked between 3 and 6 months. Following SPI there was a significant reduction in fasting glucose, fasting insulin, insulin resistance, and systolic blood pressure whereas no significant changes in these parameters was observed with SP. There were no significant changes in fasting lipid profile and diastolic blood pressure with either preparation. There was a significant increase in TSH and reduction in free thyroxine (p < 0.01) with SPI supplementation though free tri-iodothyronine was unchanged. In conclusion, soy protein with isoflavones may confer a beneficial effect on bone health, analogous to the mode of action of antiresorptive agents, albeit to a less magnitude. There was a significant improvement of cardiovascular risk markers, but a significant increase in TSH and reduction in free thyroxine after SPI supplementation indicating a detrimental effect on thyroid function.

show abstract

Section: Discussionmentioning

confidence: 99%

Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial

Sathyapalan

Aye

Rigby

et al. 2016

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…Human studies including observational and clinical trial studies also support favorable effects of isoflavones showing the results such as increasing bone mineral density and bone mechanical strength, and inhibiting bone turnover in postmenopausal women (Atmaca et al, 2008). Ingestion of isoflavones (more than 90 mg/day of isoflavones) at least 6 months have a significant effect for increasing spine bone mineral density in meta-analyses for randomized controlled trials however the effects on hip and leg bones are controversial (Taku et al, 2010). Long term safety and efficacy for isoflavones ingestion is needed to be confirmed.…”

Section: Bone Healthmentioning

confidence: 92%

Isoflavones: Chemistry, Analysis, Functions and Effects on Health and Cancer

2014

Asian Pacific Journal of Cancer Prevention

126

100

View full text Add to dashboard Cite

“…Soy isoflavones are an important class of flavonoids that include genistein and daidzein, also classified as phytoestrogens, that have been extensively studied for their beneficial effects on endothelial function [138], osteoporosis [139], endometrial hyperplasia [140], cardiovascular system and homocysteine levels [141].…”

Section: Soy Isoflavonesmentioning

confidence: 99%

“…Another meta-analysis of RCTs assessing the effects of soy isoflavone supplementation on bone turnover markers in postmenopausal women, revealed that isoflavone moderately decreased urinary deoxypyridinoline (DPD), a bone resorption marker, but did not affect serum bone alkaline phosphatase and serum osteocalcin, 2 bone formation markers [139]. It should be mentioned that some of the above mentioned effects in postmenopausal women, can be best ascribed to the estrogenic effect of isoflavones and not their antioxidant capacity.…”

Section: Soy Isoflavonesmentioning

confidence: 99%

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

Miotto¹,

Striebel²,

Cho

et al. 2013

Drug and Alcohol Dependence

121

View full text Add to dashboard Cite

Abstract:Reactive oxygen species (ROS) are widely believed to cause or aggravate several human pathologies such as neurodegenerative diseases, cancer, stroke and many other ailments. Antioxidants are assumed to counteract the harmful effects of ROS and therefore prevent or treat oxidative stress-related diseases. In this report, recent human studies exploring the efficiency of antioxidants in prevention and treatment of various diseases are reviewed. Few antioxidants including edaravone (for ischemic stroke in Japan), Nacetylcysteine (for acetaminophen toxicity), alfa-lipoic acid (for diabetic neuropathy) and some flavonoids (polyphenolic compounds present in dietary plants), such as micronized purified flavonoid fraction (diosmin and hesperidin) and oxerutins (for chronic venous insufficiency) as well as baicalein and catechins (for osteoarthritis) have found accepted clinical use. However, despite much enthusiasm in the 1980s and 1990s, many well-known agents such as antioxidant vitamins and also more recently developed compounds such as nitrones have not successfully passed the scrutiny of clinical trials for prevention and treatment of various diseases. This has given rise to a pessimistic view of antioxidant therapy, however, the evidence from human epidemiological studies about the beneficial effects of dietary antioxidants and preclinical in vitro and animal data are compelling. We have probably wasted too much time on agents like antioxidant vitamins instead of focusing on more disease specific, target-directed, highly bioavailable antioxidants. We here discuss possible reasons for the lack of success in some clinical trials and seek to provide some suggestions to be considered if antioxidant therapy is to succeed as an effective therapeutic strategy.

show abstract

Effects of soy isoflavone supplements on bone turnover markers in menopausal women: Systematic review and meta-analysis of randomized controlled trials

Cited by 149 publications

References 69 publications

Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial

Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial

Isoflavones: Chemistry, Analysis, Functions and Effects on Health and Cancer

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

Contact Info

Product

Resources

About